Immunicon restructures

IMMC restructured and reduced its headcount by about 25%. Most of the cuts were in R&D, operations and support functions related to development programs that are now completed, including IMMC's next-generation cell analysis platform, CellTracks Analyzer II, which was launched in June. IMMC said that it will continue to develop its CellSearch Circulating Tumor Kit for metastatic colorectal and prostate cancer. Johnson & Johnson (JNJ) subsidiary Veridex sells the kit for in vitro diagnostic use in metastatic breast cancer. ...